Latest Financial Results
Q1 2022
Quarter Ended Jun 30, 2021
Stock Information
Company Overview
Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company’s novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery – all which could help to increase treatment compliance and improve patient outcomes.
The Company’s three lead clinical assets have all been granted Orphan Drug Designation by the FDA providing seven years of marketing exclusivity post-launch in the United States and are protected by over 40 granted and pending patents. The lead assets target underserved orphan diseases: (i) GTX-104, an intravenous infusion targeting Subarachnoid Hemorrhage (SAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; (ii) GTX-102, an oral mucosal spray targeting Ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability, for which no treatment currently exists; and (iii) GTX-101, a topical spray, targeting Postherpetic Neuralgia (PHN), a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles), which may persist for months and even years.
Acasti-Grace Acquisition: Investor Presentation - September 2021
Download Acasti-Grace Acquisition: Investor Presentation - September 2021
Investor Contact Information
Company
Acasti Pharma Inc.
3009 Boul. de la Concorde E.
Suite 102
Laval , Québec H7E 2B5
Canada
Suite 102
Laval , Québec H7E 2B5
Canada
685 US Highway One
North Brunswick , NJ 08902
North Brunswick , NJ 08902
Investor Relations
Crescendo Communications, LLC
Chrysler Building - 405 Lexington Ave
9th Floor, Suite 9034
New York, NY 10174
T: 212-671-1020
ACST@crescendo-ir.com
Transfer Agent
Computershare Trust Company of Canada
650 de Maisonneuve West
7th Floor
Montreal, QC H3A 3T2
T: 514-982-7888
www.computershare.com/ca